acib works at the interface of fundamental and applied research. The close co-operation with and co-financing by company partners within the acib consortium guarantees the application-orientation of the centre’s research. Additionally, acib cooperates with many companies within EU programmes.
The core business of AB Enzymes is to develop new enzyme products and to sell enzyme products worldwide for the baking, beverage, animal feed, textile fibre modifications and pulp & paper markets. AB Enzymes contributes with experience and in-kind contributions in the field of filamentous fungi. These organisms are of primary interest to ABE as protein production hosts.
ABiTEP is a Berlin-Adlershof based private biotech company founded in 2005. They produce and distribute natural microbial products for use in agriculture and gardening as well as biological cleaning agents for industry, commerce and household. Other important activities are contract production and research. In addition ABiTEP is involved in various research projects developing modern and ecologically beneficial methods of plant production.
ABiTEP uses the potential of naturally occurring soil bacteria and other microorganisms to produce innovative and environmentally friendly bio-agents supporting a resource conserving, sustainable agriculture. The ABiTEP GmbH is also an active member of the Association of Manufacturers of biocontrol agents Germany/Austria and an apprenticing company.
ARAConsult defines itself as specialists for a sensible field in any project cycle of wastewater treatment/biogas production.
During many years of professional experience in the field of this current specialization ARAConsult acquired extensive and very specific know-how. Such knowledge is usually not available with staff of generalists, who lack a constant all year need for these services.
Consequently they work highly efficient and innovative, which enables ARAConsult – to our client’s advantage – to develop very cost efficient technical solutions both in terms of investment and operation.
Repligen is a bioprocessing-focused life sciences company bringing over 30 years of expertise and innovation to our customers. We are inspiring advances in bioprocessing through the development and commercialization of high-value products and flexible solutions that address critical steps in the production of biologic drugs, principally monoclonal antibodies.
Our core Protein A affinity ligands business is complemented by an expanding suite of technology-leading bioprocessing products that we sell direct to biopharmaceutical companies and contract manufacturers worldwide. All of our bioprocessing products are meaningfully differentiated from alternatives to the benefit of our customers. Our Protein A ligands are used to purify over 50 monoclonal antibody-based drugs on the market and more than 300 in clinical development. Our XCell™ ATF cell concentration device, and LONG® cell culture supplements are at the forefront of innovation in bioprocessing. To provide customers with the broadest selection of OPUS® pre-packed chromatography columns from bench-scale to production-scale, Repligen acquired Atoll GmBH of Weingarten, Germany, solidifying Repligen as a leading supplier in this fast-growing segment
BASF is an industrial partner of ACIB with strong interest in biocatalytic synthesis (flavoproteins, C=C-reduction, cyclisation, C-C-bond formation, selective oxidation, screening and modelling for optimisation of biocatalysts), polymer-modifying enzymes, functional polymers and functionalisation of polymers.
Bio-ferm is an Austrian company that develops, produces and sells innovative biotechnological plant protection products. All products were developed in-house, in cooperation with the University of Konstanz. Bio-ferm supports ACIB with its knowhow in large scale fermentation and registration of microbial plant protection products. Furthermore, the screening for new efficient microbial antagonists will be supported by the conduction of greenhouse and field trials.
BIOCRATES life science AG has established an integrated technology platform for comprehensive metabolomics, allowing the simultaneous detection and quantitation of more than 1000 metabolites. In particular BIOCRATES contributes its analytical and scientific expertise and wants to participate in the development of new analytical assays.
BIOMIN Holding GmbH, located in Herzogenburg and Tulln (BIOMIN Research Center), is a medium size Austrian company focusing on the development and manufacturing of innovative biological feed additives. BIOMIN’s experience in animal nutrition, including well-established methods for analysis of feed contaminants, also expands the scope of the ACIB project platform.
Biotenzz Gesellschaft für Biotechnologie mbH
Biotenzz Gesellschaft für Biotechnologie mbH, a spin-off company, develops and produces biological agents on the basis of naturally occurring microorganisms for pest management in agricultural production. Biotenzz Gesellschaft für Biotechnologie mbH is an industrial partner complementary to two other company partners within the projects focusing on bioprocess development. The company provides immobilization and fermentation expertise.
The founders of the company are individuals (80%) and the Institute of Agricultural Microbiology (20%). The main activity of the company Bisolbi-Inter is the production of microbiological preparations and fertilizers for agriculture and forestry, development of promising new drugs and microbiological fertilizers and the development of technologies for recycling food and wood processing industry. The company is patent holder four patents – one patent transferred to the phase of the international registration in the EU – and nine trademarks. Since 2002 Bisolbi is member of IFOAM-International Federation of Organic Agriculture, since 2006 member of the Non-Profit Partnership “Biomak”, since 2011 member of the Non-Commercial Partnership “union of enterprises of the biotechnology industry” and a member of the Technology Platform “Bioindustry Bioresources – BioTeh2030”.
BI RCV produces biopharmaceuticals for clinical trial of pharmaceutical products. In ACIB BI RCV wants to participate in the development of new expression systems, new production systems in downstream processing and the development of tools for advanced bioprocess monitoring to gain real time insight into the cell factory, as well as better process and systems understanding.
As today’s chemicals industry reaches a major turning point in its history and focuses on more environmentally-responsible products and processes, the sustainability of tomorrow’s “green” chemistry nonetheless depends on its capacity to exploit the exceptional properties of natural biological catalysts – or enzymes – on an industrial scale. It will also depend on whether bioprocesses can be custom-designed from the outset to adapt enzyme properties to meet the competitive and performance requirements of manufacturers, and transform green chemistry into industrial reality.
A pioneer and driving force in this transformation, CARBIOS’ expert knowledge and research into enzymes means it is able to offer manufacturers cutting-edge technologies and bioprocesses with a high value added.
Chorus GmbH is focused on the establishment of a comprehensive, fast and efficient cell line development and production pipeline that allows the rapid production of material for the pre-clinic. In ACIB Chrous will contribute to the development of tools and methods for the characterisation of CHO cells used for production of biopharmaceutical products.
The Swiss based Clariant AG works in 11 business units such as the the developement of innovative system solutions for the utilisation of renewable resources and renewable energy sources. Within ACIB, Clariant plans to provide guidance on the development of innovative biocatalysts and strains, in particular for production of technical enzymes.
CNA Diagnostics is currently developing rapid and cost-effective molecular testing systems for major bovine diseases.
When animals contract diseases such as Bovine Spongiform Encephalopathy, Johne’s disease or Bovine Respiratory disease, their body responds to the stress by releasing exosomes containing specific DNA molecules into the blood. This disease-specific process begins in the early stages of chronic diseases, often before any clinical signs can be observed.
CNAD expects that through the application of their molecular diagnostic technology, which is based on the detection of these specific DNA sequences, animals carrying diseases critical to the industry can be identified much earlier than currently possible (before the first clinical signs), and with better sensitivity and specificity.
It CNADs our goal to significantly improve the food safety for consumers, while increasing profitability for the livestock industry at the same time.
DPx Holdings, formed by combining DSM Pharmaceutical Products and Patheon Inc., is a leading provider of CDMO services, pharmaceutical products and other formulated products for various industries. The company was formed in 2014 as a result of the merger of Patheon and DSM Pharmaceutical Products and is owned by JLL Partners and Royal DSM. With a global headquarters in Durham, N.C., DPx Holdings has a footprint of more than 20 locations across North America, Europe, Latin America and Australia with more than 8,000 employees.
DSM creates innovative products and services in Life Sciences and Materials Sciences, contributing to quality of life. DSM’s products and services are used globally in a wide range of markets and applications. In ACIB DSM continues a long term partnership with A-B. DSM acts as a group partner, with, projects being undertaken by three divisions within DSM, namely DSM Fine Chemicals, DSM Nutritional Products and DSM Performance Materials.
Evonik is one of the world’s leading specialty chemicals companies. The central elements of their strategy for sustained value creation are profitable growth, efficiency and values. Around 80 percent of sales come from market-leading positions, which Evonik is systematically
expanding. The company concentrates on high-growth megatrends, especially health, nutrition, resource efficiency and globalization.
In 2014 Evonik’s roughly 33,000 employees generated sales of €12.91)billion and an operating result (adjusted EBITDA) of €1.9 billion. Around 78 percent of sales are generated outside Germany, providing convincing evidence that Evonik Industries’ business is global.
Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. In ACIB Roche participates in the development of expression systems and the optimisation of biotransformations using these enzymes towards preparative applicability and on a larger scale.
GALAB is an independent service laboratory for external quality control. They analyse and evaluate food, food packaging, sanitary products, industrial products, biopharmaceutical products or the environment for substances or contaminants. GALAB supports customers with a competent and innovative team focused on reaching solutions for your specific needs.
G.L. Pharma was formed out of a merger of the two pharmaceutical companies Gerot and Lannacher and is looking back at a history of more than 60 years.
Gerot Lannach develops, produces and allocates unique brand name products as well as generics for the well-being of people in Austria and abroad. As a supplier to Austria’s healthcare sector, the company partners with general practitioners, pharmacists, their patients and pharmaceutical wholesalers.
As an international player, G.L. Pharma markets its products through our licensees and branch offices to more than 30 countries. The core competence concentrates on three different business areas cardiovascular system, central nervous system and urology, oncology, opioid substitution therapy.
HocusLocus, LLC is exploiting a novel regulatory mechanism in which one RNA sequence changes the structure of another RNA sequence. Called structurally interacting RNA or sxRNA, the “Tenenbaum Lab” at the University at Albany has described how miRNA use this interaction to control protein binding to an mRNA. Broadly speaking, sxRNA provides a method to make an aptamer “switchable”, i.e. the aptamer is functional or not as a result of a trans-interaction with a miRNA.
HocusLocus is using this mechanism both to control translation of an mRNA to achieve the ability to selectively express protein in specific cell types, and to create a new class of miRNA inhibitors.
Formerly Infact GesbR, the company was reorganized with the idea of the development of a new technology for early detection of infections. The Qualizyme technology is based on the fact that the initiation of an infection is associated with the release of specific combinations of anti-bacterial enzymes which can be easily detected and quantified. These early biomarkers are being developed by our scientific teams into kits and devices for clinical and veterinary use.
As a small company located in Rottenmann, Upper Styria, IPUS is a specialist for immobilisation of anaerobic microbial cultures and offers modern tools for population analysis and has also gathered deep knowledge of anaerobia cultivation.
Jungbunzlauer is one of the world’s leading producers of natural and nature-identical biodegradable ingredients. In ACIB Jungbunzlauer Austria participates in the development and application of transcriptomic and metabolomic methods for analysis and improvement of microbial production strains.
KWS ranks among the world‘s leading plant breeding companies, is an independent breeding company and leader in sales of sugar beet seed. In ACIB KWS is especially interested in the implementation of microorganisms or novel bio-active compounds derived from microorganisms in conventional and organic seed coatings to protect treated plants against diseases, which are currently difficult to control.
Lactosan is a service company with international presence. Their policy is highest possible efficiency and top – quality. Lactosan is able to reduce the customers “time to market“ due to integrated, flexible solutions. Their comprehensive know-how, established over many years, is the solid basis which assures optimum security and cost-efficiency for clients.
Lonza is one of the world’s leading suppliers to the pharmaceutical, healthcare and life science industries. Lonza produces active pharmaceutical ingredients both chemically as well as biotechnologically In ACIB Lonza contributes to the production of recombinant proteins and the development of new biocatalysts for complex reactions. Lonza’s expertise in process development will contribute to bringing these biocatalysts to industrial applicability.
Microinnova makes chemical processing more efficient. The company develops customer specific high tech solutions based on flow chemistry and other process intensification technologies like microreactors or ultrasound. A competent team of chemists and engineers provides products like flow mini-plants and manufacturing plants as well as services like development and engineering. It is Microinnovas aim to turn process performance into money for the customers.
The Cologne-based industrialists Emil Pfeifer, Eugen Langen and Valentin Pfeifer founded the company Pfeifer & Langen in 1870.
The Rheinish region developed soon and became a center of the modern sugar economy. Today, Pfeifer & Langen is one of the major sugar producers in Europe and offers (under the brand names Diamond sugar and sugar Cologne) a variety of high quality products.
Pyro Science is a manufacturer of high-precision optical oxygen sensors based on unique optical detection techniques (REDFLASH technology). The product line ranges from microsensors to robust miniprobes and contactless sensors working both in gas and liquids. The companies complete plug&play solutions are widely used in scientific and industrial applications. Additionally, Pyro Science gained a strong position in offering custom solutions for industrial partners.
Roal Ltd is one of the world´s largest enzyme companies. They produce enzymes for different industrial applications, e.g. baking, food, technical and feed industries. Roals core competence areas are Trichoderma, Aspergillus and Bacillus-fermentations. In their process they combine long term biotechnical research and knowledge with modern technology and professional personnel.
Roal Oy and manufacturing facilities are located in Rajamäki, 50 km north of Finlands capital Helsinki. Over 90 % of thier products are exported worldwide.
Roal was established in 1991 as a joint venture by former Finnish Alko Ltd and German Röhm GmbH. Both companies had a decades-long history in enzyme research and production. Today Roal is proud to be owned by Altia and Associated British Foods. In the marketing and selling of products Roal co-operates with AB Enzymes.
As a company, Roal is striving for greater customer orientation and satisfaction. They do this by ensuring excellent product quality and “on time in full” deliveries to the customer – every day. By running the business efficiently and profitably, Roal wants to earn the owners´ and stakeholders´ trust.
As an employer, Roals main focus is on offering the employees a fair and safe place to work with a spirit of continuous improvement. As a production site Roal continuously improves the environmental aspects of the process and products.
In the course of a project initiated by Ortner Reinraumtechnik GmbH in close cooperation with the Institute for Environmental Biotechnology (Graz University of Technology) and the Research Center Pharmaceutical Engineering, the antagonistic effect of beneficial microorganisms on clinical relevant microorganisms was extensively studied. In order to make the promising results applicable for a wide range of industrial applications, the Roombiotic GmbH was founded in the year 2013. The team of Roombiotic is focused on the development of innovative decontamination technologies based on biogenic airborne antimicrobial substances.
The R&D department of Roombiotic has already identified several candidates of volatile substances produced by beneficial bacteria which express a strong antimicrobial activity at low concentrations against a broad spectrum of microbes, including bacteria (Staphylococcus aureus, MRSA, Escherichia coli, Pseudomonas aeruginosa, Bacillus sp., Nocardia sp.), yeast (Candida albicans) and molds (Penicillium sp., Aspergillus sp., Cladiosporum sp.).
The Sandoz sites in Kundl and Schaftenau are specialists for industrial biotechnological processes and have built-up extensive expertise on large scale-fermentation production processes and the enzymatic and chemical modification of bulk-antibiotics. In acib, Sandoz continues its long-established participation in the precursor centres A-B and ACBT. Sandoz is committed to research projects in biocatalytic synthesis, cell factories, protein design and engineering as well as in bioprocess engineering.
The goal of Syconium Lactic Acid GmbH (SLA) is to develop a novel production solution for lactic acid combining novel genetically modified yeast strain and an aligned fermentation process for a significantly reduction of
Synovo is a pharmaceutical discovery services company providing services in diverse fields. Main activities are based on assays and models for the selection of drug candidates. Synovo is engaged in projects in the fields of anti-inflammatory and immune suppressive drug optimisation. Synovo participates in a new multifirm project focused at bioresponsive systems.
Themis Bioscience is a start-up biotechnology company developing vaccines to prevent infectious diseases. The company’s development focus is primarily concentrated on emerging and specialist indications, advancing promising vaccines from preclinical to late-stage clinical development phases.
Themis aims to exploit the increasing licensing and acquisition trend to generate value by developing and partnering our technology programs and vaccine candidates. It is their mission to establish Themis as a first class biotech development boutique and to become a preferred licensing partner for leading biotech and pharmaceutical companies.
Themis’ core lead technology, Themaxyn™ – a highly novel, patent-protected, and innovative vaccine platform which originates from a world-leading European vaccine research institute – will be used to create novel vaccines. The Company’s first vaccine targets are emerging tropical and travelers diseases, including dengue, chikungunya and yellow fever virus, and there is clear potential to expand the Themaxyn™ technology to further indications.
Themis was founded in September 2009 and is based in Vienna. The founders and management team includes experienced vaccine experts with successful, established track records in the biotechnology industry and have worked alongside each other for a number of years.
As a world-leading organization with a unique portfolio of products, focused on Pharma, Personal Care and Colour Chemistry, Vivimed provides high performance products of quality and value to improve the lives of their clients’ consumers.
Vivimed has offices in India, China, Europe and USA, with manufacturing facilities focused around Hyderabad city in India. What began as a small, entrepreneurial family-operated business now provides a diverse portfolio of products to consumers across nearly 50 countries. The company is now set to expand its operations into the fast-emerging and highly demanding sector of Printable Electronics and Organic Semiconductors.
The voestalpine Group is a steel-based technology and capital goods group that operates worldwide. With around 500 Group companies and locations in more than 50 countries and on all five continents, the Group has been listed on the Vienna Stock Exchange since 1995.
Headquartered in Linz, voestalpine is represented by 500 Group companies and locations in more than 50 countries on five continents. The Group consists of four divisions.
With its top-quality products, the Group is one of the leading partners for the automotive and consumer goods industries in Europe and for the oil and gas industries worldwide. The voestalpine Group is also the world market leader in turnout technology, special rails, tool steel and special sections. In the business year 2013/14, the voestalpine Group reported a revenue of EUR 11.2 billion and an operating result (EBITDA) of EUR 1.4 billion, voestalpine counts around 48,100 employees worldwide.